Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol

European Heart Journal

Volumn 37, Issue 25, 2016, Pages 1967-1976

  Laaksonen, Reijo ^a,b,c   Ekroos, Kim ^a   Sysi Aho, Marko ^a   Hilvo, Mika ^a   Vihervaara, Terhi ^a   Kauhanen, Dimple ^a   Suoniemi, Matti ^a   Hurme, Reini ^a   März, Winfried ^d,e   Scharnagl, Hubert ^f   Stojakovic, Tatjana ^f   Vlachopoulou, Efthymia ^g   Lokki, Marja Liisa ^g   Nieminen, Markku S ^g,h   Klingenberg, Roland ⁱ   Matter, Christian M ⁱ   Hornemann, Thorsten ^j   Jüni, Peter ^k   Rodondi, Nicolas ^l,m   Räber, Lorenz ^l   Windecker, Stephan ^l   Gencer, Baris ⁿ   Pedersen, Eva Ringdal ^o   Tell, Grethe S ^o   Nygård, Ottar ^o,p   Mach, Francois ⁿ   Sinisalo, Juha ^g,h   Lüscher, Thomas F ^j   more..

^a Zora Biosciences   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e SYNLAB ACADEMY   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g UNIVERSITY OF HELSINKI   (Finland)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k ST MICHAEL'S HOSPITAL   (Canada)

^l UNIVERSITY OF BERN   (Switzerland)

^m UNIVERSITY OF LAUSANNE   (Switzerland)

ⁿ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^o UNIVERSITY OF BERGEN   (Norway)

^p HAUKELAND UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Acute coronary syndrome; Biomarker; Ceramide; Coronary artery disease; LDL cholesterol; Prognosis; Risk prediction

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; RISK FACTOR;

ACUTE CORONARY SYNDROME; BIOMARKERS; CERAMIDES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84977519129     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw148     Document Type: Article

References (30)

1. Morrow DA. Cardiovascular risk prediction in patients with stable and unstable coronary heart disease. Circulation 2010;121:2681-2691.
2. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, WijnsW, Zahger D. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevatio. Eur Heart J 2011;32:2999-3054.
3. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot J-S, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, SabatéM, Senior R, Taggart DP, van der Wall EE, Vrints CJM, Zamorano JL, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Valgimigli M, Claeys MJ, Donner-Banzhoff N, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Husted S, James SK, Kervinen K, Kristensen SD, Pietro MA, Pries AR, Romeo F, Ryden L, Simoons ML, Steg PG, Timmis A, Yildirir A. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
4. Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvanne T, Hurme R, Gouni-Berthold I, Berthold HK, Kleber ME, Laaksonen R, MarzW. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab 2014;99:E45-E52.
5. Meikle PJ, Wong G, Tsorotes D, Barlow CK, Weir JM, Christopher MJ, MacIntosh GL, Goudey B, Stern L, Kowalczyk A, Haviv I, White AJ, Dart AM, Duffy SJ, Jennings GL, Kingwell BA, Weir M. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol 2011;31: 2723-2732.
6. Fernandez C, Sandin M, Sampaio JL, Almgren P, Narkiewicz K, Hoffmann M, Hedner T, Wahlstrand B, Simons K, Shevchenko A, James P, Melander O. Plasma lipid composition and risk of developing cardiovascular disease. PLoS ONE 2013;8: e71846.
7. Cheng JM, Garcia-Garcia HM, de Boer SPM, Kardys I, Heo JH, Akkerhuis KM, Oemrawsingh RM, van Domburg RT, Ligthart J, Witberg KT, Regar E, Serruys PW, van Geuns R-J, Boersma E. In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Eur Heart J 2014;35:639-647.
8. Bismuth J, Lin P, Yao Q, Chen C. Ceramide: a common pathway for atherosclerosis? Atherosclerosis 2008;196:497-504.
9. Menuz V, Howell KS, Gentina S, Epstein S, Riezman I, Fornallaz-mulhauser M, Hengartner MO, Gomez M, Riezman H, Martinou J. Protection of C. elegans from Anoxia by HYL-2 Ceramide Synthase. Science 2009;324:381-384.
10. Park J-W, Park W-J, Futerman AH. Ceramide synthases as potential targets for therapeutic intervention in human diseases. Biochim Biophys Acta 2014;1841: 671-681.
11. Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, Mauer J, Xu E, Hammerschmidt P, Bronneke HS, Trifunovic A, LoSasso G, Wunderlich FT, Kornfeld J-W, Bluher M, Kronke M, Bruning JC. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 2014;20:678-686.
12. Raichur S, Wang ST, Chan PW, Li Y, Ching J, Chaurasia B, Dogra S, O hman MK, Takeda K, Sugii S, Pewzner-Jung Y, Futerman AH, Summers SA. CerS2 haploinsufficiency inhibits b-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab 2014;20:687-695.
13. Kauhanen D, Sysi-Aho M, Koistinen KM, Laaksonen R, Sinisalo J, Ekroos K. Development and validation of a high-throughput LC-MS/MS assay for routine measurement of molecular ceramides. Anal Bioanal Chem 2016. doi:10.1007/ s00216-016-9425-z.
14. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KAA. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163:2345-2353.
15. Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB, Friedlander D, White H, Thompson P, Tonkin A. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol 2001;38:56-63.
16. Pencina MJ, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172. Discussion 207-212.
17. Battes L, Akkerhuis KM, Van Boven N, Boersma E, Kardys I. Cardiovascular risk prediction models in patients with stable coronary artery disease. Exp Clin Cardiol 2014;20:117-130.
18. Xu J, Yeh CH, Chen S, He L, Sensi SL, Canzoniero LM, ChoiDW, Hsu CY. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/ cycloheximide-induced cerebral endothelial cell death. J Biol Chem 1998;273: 16521-6.
19. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996;274:1855-1859.
20. Lozanski G, Berthier F, Kushner I. The sphingomyelin-ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A, but not alpha-fibrinogen. Biochem J 1997;328(Pt 1):271-275.
21. Hamada Y, Nagasaki H, Fujiya A, Seino Y, Shang Q-L, Suzuki T, Hashimoto H, Oiso Y. Involvement of de novo ceramide synthesis in pro-inflammatory adipokine secretion and adipocyte-macrophage interaction. J Nutr Biochem 2014;25: 1309-1316.
22. Billich A, Baumruker T. Sphingolipid metabolizing enzymes as novel therapeutic targets. Subcell Biochem 2008;49:487-522.
23. Janis MT, Tarasov K, Ta HX, Suoniemi M, Ekroos K, Hurme R, Lehtimaki T, Paiva H, Kleber ME, Marz W, Prat A, Seidah NG, Laaksonen R. Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency. Atherosclerosis 2013;228:380-385.
24. Sachdeva A, Cannon CP, Deedwania PC, Labresh K a, Smith SC, Dai D, Hernandez A, Fonarow GC. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136 905 hospitalizations in get with the Guidelines. Am Heart J 2009;157:111-7.e2.
25. Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005;26:890-896.
26. Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 2013; 128:2395-2403.
27. Gierens H, Nauck M, Roth M, Schinker R, Schurmann C, Scharnagl H, Neuhaus G, Wieland H, Marz W. Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler Thromb Vasc Biol 2000;20:1777-1783.
28. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1. Circ Res 2016; 118:145-156.
29. Fekry B, Esmaeilniakooshkghazi A, Krupenko SA, Krupenko NI. Ceramide synthase 6 Is a novel target of methotrexate mediating its antiproliferative effect in a p53-dependent manner. PLoS ONE 2016;11:e0146618.
30. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, Stricker B, Mendis S, Hofman A, Mant J, Franco OH. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34: 2940-2948.